Impact BioMedical, INC. Other General Expense
Impact BioMedical, INC. (IBO) reported Other General Expense of $184.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-20.
Discontinued › Operating Expenses
us-gaap:OtherGeneralExpense · last filed 2024-02-20
- Impact BioMedical, INC. other general expense for the quarter ending 2023-12-31 was $122.00K, a 335.71% increase year-over-year.
- Impact BioMedical, INC. other general expense for the quarter ending 2023-09-30 was $23.00K, a 228.57% increase year-over-year.
- Impact BioMedical, INC. other general expense for the quarter ending 2023-06-30 was $14.00K, a 51.72% decline year-over-year.
- Impact BioMedical, INC. other general expense for the quarter ending 2023-03-31 was $25.00K.
- Impact BioMedical, INC. other general expense for fiscal 2023 was $184.00K, a 170.59% increase from fiscal 2022.
- Impact BioMedical, INC. other general expense for fiscal 2022 was $68.00K.
| Period end | Other General Expense 3 month | Other General Expense 6 month | Other General Expense 9 month | Other General Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $145.00K derived: sum of 2 quarters · filed 2024-02-20 | $159.00K derived: sum of 3 quarters · filed 2024-02-20 | $184.00K 10-K · filed 2024-02-20 |
| 2023-09-30 | $23.00K 10-Q · filed 2023-11-13 | $37.00K derived: sum of 2 quarters · filed 2023-11-13 | $62.00K 10-Q · filed 2023-11-13 | $90.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2023-06-30 | $14.00K 10-Q · filed 2023-10-05 | $39.00K 10-Q · filed 2023-10-05 | $67.00K derived: sum of 3 quarters · filed 2024-02-20 | $74.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2023-03-31 | $25.00K derived: 10-K 12 month − 3 quarters · filed 2024-02-20 | $53.00K derived: sum of 2 quarters · filed 2024-02-20 | $60.00K derived: sum of 3 quarters · filed 2024-02-20 | $89.00K derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $35.00K derived: sum of 2 quarters · filed 2024-02-20 | $64.00K derived: sum of 3 quarters · filed 2024-02-20 | $68.00K 10-K · filed 2024-02-20 |
| 2022-09-30 | $7.00K 10-Q · filed 2023-11-13 | $36.00K derived: sum of 2 quarters · filed 2023-11-13 | $40.00K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $29.00K 10-Q · filed 2023-10-05 | $55.00K 10-Q · filed 2023-10-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |